11 Atrial Fibrillation Clinical Trials in Tampa, FL (2026)

Q: How do I join a clinical trial in Tampa?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Tampa research site will contact you.

Recruiting Atrial Fibrillation Studies in Tampa

NCT06578104Recruiting

PULSED AF Post-Approval Study

PULSED AF PAS is a prospective, global, multi-center, non-randomized, observational trial. Subjects will be treated with the PulseSelect™ PFA System and followed through 36 months....

Tampa, FL580 participantsMedtronic Cardiac Ablation Solutions

View Study Details

NCT06935591Recruiting

Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study

The goal of this clinical trial is to compare the use of the Vektor Computational ECG Mapping System (vMap®) with pulmonary vein isolation (PVI), to using PVI alone, to treat Atrial Fibrillation (AF) ...

Tampa, FLNA423 participantsVektor Medical

View Study Details

NCT06735534Recruiting

Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

The ReMATCH Study is a prospective, single arm, open label, multi-center, study utilizing the FARAPULSE PFA System, including the FARAWAVE and FARAPOINT PFA Catheters....

Tampa, FLNA376 participantsBoston Scientific Corporation

View Study Details

NCT04710576Recruiting

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host diseas...

Tampa, FLPHASE2296 participantsSyndax Pharmaceuticals

View Study Details

NCT04380740Recruiting

Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis

This is a multicenter randomized, double blind, Phase 2 trial for patients receiving transplants from 7 of 8 HLA matched donors, in which an extended dosing regimen of abatacept, and a short-term dosi...

Tampa, FLPHASE2160 participantsBoston Children's Hospital

View Study Details

NCT06660355Recruiting

Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy

Allogeneic transplant is potentially curative for hematological malignancies but its use is limited by the development of GVHD. Ruxolitinib now has FDA approval for treatment of chronic GVHD that has ...

Tampa, FLPHASE2120 participantsH. Lee Moffitt Cancer Center and Research Institute

View Study Details

NCT06936566Recruiting

MAGIC Ruxolitinib for aGVHD

This clinical trial will study ruxolitinib-based treatment of acute graft-versus-host-disease (GVHD) that developed following allogeneic hematopoietic cell transplant. Acute GVHD occurs when donor cel...

Tampa, FLPHASE298 participantsJohn Levine

View Study Details

NCT05996627Recruiting

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem ...

Tampa, FLPHASE282 participantsFred Hutchinson Cancer Center

View Study Details

NCT07011810Recruiting

Axatilimab for Sclerotic Chronic Graft-versus-Host Disease

This phase II trial tests how well axatilimab works in treating patients with thickening or hardening (sclerosis) of the skin related to chronic graft-versus-host disease after a donor stem cell trans...

Tampa, FLPHASE250 participantsFred Hutchinson Cancer Center

View Study Details

NCT06619561Recruiting

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD. Participants will be treated with vimseltinib in...

Tampa, FLPHASE248 participantsDeciphera Pharmaceuticals, LLC

View Study Details

NCT02932007Recruiting

Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study

The goal of this pilot study is to explore the efficacy of chloroquine in terminating persistent AF and assess its potential role as a pharmacological cardioversion agent for the management of AF....

Tampa, FLPHASE240 participantsUniversity of South Florida

View Study Details

About Atrial Fibrillation Clinical Trials in Tampa

Atrial fibrillation (AFib) is the most common type of heart arrhythmia, causing an irregular and often rapid heartbeat. It significantly increases the risk of stroke, heart failure, and other complications. Treatment includes blood thinners, heart rate or rhythm control medications, and procedures like ablation.

There are currently 11 atrial fibrillation clinical trials recruiting participants in Tampa, FL. These studies are seeking a combined 2,273 participants. Research is being sponsored by Medtronic Cardiac Ablation Solutions, Vektor Medical, Boston Scientific Corporation and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atrial Fibrillation Clinical Trials in Tampa — FAQ

Are there atrial fibrillation clinical trials in Tampa?

Yes, there are 11 atrial fibrillation clinical trials currently recruiting in Tampa, FL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Tampa?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tampa research site will contact you about next steps.

Are clinical trials in Tampa free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tampa studies also compensate for your time and travel.

What atrial fibrillation treatments are being tested?

The 11 active trials in Tampa are testing new therapies including novel drugs, biologics, and treatment approaches for atrial fibrillation.

Data updated July 18, 2026 from ClinicalTrials.gov